Gan Ning is used for short-term symptomatic support across conditions presenting with acute episodes like the common cold, influenza, and related upper respiratory infections. This combination is intended for use across domains where additional symptomatic support is needed. It is applied when groups of symptoms create noticeable functional strain. The support offered is intended to contribute to easing the overall symptom load, which may help patients cope during difficult acute episodes.

Its use is relevant for managing key manifestations, which includes mild to moderate pain, headaches, fever, and nasal congestion/sinus pressure. It is used to help address the combined discomfort of systemic imbalance and localized respiratory distress.

It is relevant for managing symptoms that may appear suddenly and create noticeable physiological strain.

“This therapeutic approach is designed to support patients during difficult episodes by easing distress and assisting with maintaining functional stability.”

---

Quick Fact: Relief for Dual Symptoms

Quick Fact: Relief for Dual Symptoms

Its application is considered relevant for patients experiencing a combination of systemic symptoms (pain and fever) and localized respiratory symptoms (nasal and sinus blockage), and plays a role in managing multiple symptom-focused domains during acute illness.

Regulatory References

1. FDA Drug Label overview

Who Can and Cannot Use Gan Ning?

Eligibility for Gan Ning (Ibuprofen/Pseudoephedrine) is strictly determined by regulatory authorities and is not permitted for all populations. The medicine is formally approved for use by adults and adolescents 12 years of age and older. Use in children under 12 years of age is specifically contraindicated by regulatory labels.

Certain pre-existing conditions or physiological states define absolute non-eligibility based on component risks:

Status	Conditions/Populations
Contraindicated	Severe or uncontrolled hypertension, severe heart failure, active peptic ulcer, severe renal or hepatic insufficiency, use of Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of cessation, and the third trimester of pregnancy.
Use Restricted	Geriatric populations (age 60 or older) are not recommended for long-term use due to heightened risk of gastrointestinal adverse effects. Caution is required for patients with diabetes, thyroid problems, pre-existing cardiovascular disease (when not severe), or an enlarged prostate. Some European labels state use is contraindicated during breast-feeding.

Regulatory agencies impose these explicit prohibitions based on the documented risks associated with the Ibuprofen and Pseudoephedrine active ingredients, defining who is eligible under the approved general population status.

Interaction Map: Interactions with other medicines and products — official regulatory information for Gan Ning

Interaction scope

• Medicinal product categories with documented interactions: Monoamine Oxidase Inhibitors (MAOIs); Anticoagulants; Oral Corticosteroids; Antiplatelet Agents; SSRIs; Diuretics/Antihypertensives; Lithium; Methotrexate; other Sympathomimetics.
• Specific interacting medicines (if explicitly listed): Lithium, Methotrexate, Warfarin, low-dose Aspirin, Ergot Alkaloids.
• Mechanistic basis of interactions (only if stated in label): Pharmacodynamic synergism (increased GI bleeding risk; potentiation of sympathomimetic effects); Ibuprofen causing increase in plasma concentrations of certain co-administered drugs.
• Timing-based interaction rules (if applicable): Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly prohibited with or within 14 days of stopping the MAOI.
• Population-specific interaction notes (if applicable): Interaction risk for GI bleeding is heightened in the elderly (age 60 or older); caution noted for patients with pre-existing cardiovascular disorders.
• Interaction-related restrictions: Prohibition against taking other NSAIDs or other decongestants; restricted use with alcohol (ethanol), tobacco, and caffeine-containing products.

Interaction classifications (high-level)

• Interaction severity classification (as defined in official documents): Contraindicated (e.g., MAOIs, CABG surgery); Clinically Significant (e.g., Anticoagulants, Lithium); Use with Caution (e.g., Diuretics).
• Regulatory basis (EMA / FDA / etc.): Documented in government regulatory sources including FDA Prescribing Information and EMA/National Health Authority Summary of Product Characteristics.
• Interaction-context constraints (as defined in official documents): Interactions require avoiding additive GI toxicity, sympathomimetic hypertensive effects, and preventing increased systemic exposure of co-administered agents.

Resulting interaction structure Official interaction statements:

• Contraindicated with MAOIs; prohibited co-administration with other NSAIDs, other decongestants, and near Coronary Artery Bypass Graft (CABG) surgery.
• Co-administration with Anticoagulants, Corticosteroids, Antiplatelet Agents, or SSRIs may result in an increased risk of serious gastrointestinal bleeding.
• Ibuprofen is documented to cause an increase in the plasma concentrations of medicines such as Lithium and Methotrexate, and may reduce the efficacy of Diuretics.

Connection to the overall interaction profile (2–4 sentences): Regulatory documents define this product's interaction structure around distinct risks from its dual components: a significant pharmacodynamic risk of additive gastrointestinal toxicity from Ibuprofen and a sympathomimetic hypertensive risk from Pseudoephedrine. This structure dictates absolute prohibitions, such as the 14-day MAOI timing rule, and warnings regarding exposure modification for specific agents like Lithium and Methotrexate, which all users must be aware of according to official labeling.

How Gan Ning Works

Gan Ning influences multiple distinct biological systems simultaneously, which collectively shape the resulting physiological consequences. The mechanism involves modulating pathways that regulate cell integrity, decreasing the synthesis of extracellular matrix components, and influencing local inflammatory and metabolic mediators.

Targeting Cellular Defense and Stress Signals

This mechanism focuses on modulating internal cell signaling pathways, such as those governing oxidative stress and programmed cell death (apoptosis). By engaging these pathways, Gan Ning regulates pathways that contribute to cell integrity and influences systems responsible for metabolic and detoxification functions.

Interrupting the Scarring Process (Fibrosis)

Gan Ning acts as an inhibitor within the pathway responsible for tissue scarring, primarily by interfering with the activation of hepatic stellate cells and key growth factors like TGF-beta. This action influences the synthesis of collagen and other matrix proteins, which impacts the organ's structural architecture and function.

Modulating Inflammatory and Metabolic Balance

Gan Ning modulates the release of pro-inflammatory mediators while also influencing metabolic pathways, particularly those related to bile acid homeostasis. This balanced modulation influences the biochemical environment of the organ, affecting mechanisms that regulate cell turnover and physiological stability.

Administration and Dosage Principles

Gan Ning is administered via the oral route as a fixed-dose combination, typically available in tablet, caplet, or liquid-filled capsule forms. Each unit contains 200 mg Ibuprofen and 30 mg Pseudoephedrine HCl. The smallest effective dose necessary to manage symptoms is used.

Dosing Schedule and Limits

The standard adult dose, applicable to individuals 12 years of age and over, is one unit (200 mg/30 mg) taken every 4 to 6 hours while symptoms persist. If the standard dose does not adequately relieve symptoms, two units (400 mg/60 mg) may be used at the time of dosing.

A minimum interval of 4 hours must be observed between administrations. The total intake of the medicine is strictly limited to a maximum of 6 units (1200 mg Ibuprofen / 180 mg Pseudoephedrine HCl) in any 24-hour period. Use in children under 12 years of age is not recommended.

Procedural Use and Duration

To manage potential gastric discomfort, the medicine may be taken with food or milk. If a dose is missed, it should be taken as soon as possible, provided the next scheduled dose is not due within the minimum 4-hour interval; doubling doses to compensate for a missed one is not permitted. This medicine is designated for short-term use only, with a maximum treatment duration of 4 to 7 days.

Evidence for use in Acute Common Cold and Flu Symptoms

Research has been conducted to explore this combination product in adults experiencing conditions associated with acute or disruptive episodes, such as the common cold and flu. Studies include short-term, randomized trials and descriptive analyses that focused on outcomes related to systemic or functional imbalance, specifically monitoring patient-reported outcomes describing perceived discomfort. These trials monitored changes in symptom intensity or variability, including metrics for headache, fever, body aches, nasal congestion, and sinus pressure.

The populations observed were primarily adults experiencing acute episodes of cold symptoms. Studies observed that measured symptom score changes varied based on the timing of treatment initiation, specifically when use was assessed early in the course of symptoms. Pharmacokinetic studies describe the comparison of systemic exposure for both ingredients from the combination product with the exposure observed when each ingredient was studied alone. Follow-up durations were limited to the short-term course of the illness, and the research exploring symptom changes during periods of increased symptom activity provides limited insight into long-term outcomes.

Evidence for use in Seasonal Allergic Rhinitis

The research explored this combination within multi-center, randomized, controlled trials applied in research contexts involving fluctuating or unstable symptoms associated with seasonal allergies. These studies focused on outcomes describing episodic or acute changes in pain intensity (e.g., facial pain, headache) and non-pain allergy symptom scores. The trials were conducted on subjects with documented seasonal allergic rhinitis who were experiencing moderate, associated pain.

The key research for this context primarily utilized a triple-combination product that included Ibuprofen, Pseudoephedrine, and a third ingredient (an antihistamine). Trials reported a difference in the measurement of pain intensity changes from baseline when the Ibuprofen-containing regimen was assessed alongside the regimen without the analgesic component. The research highlights that the study results reflect the specific conditions of a triple-ingredient trial, which limits the direct evidence base for the two-ingredient formulation alone. The duration of these research scenarios was typically short, covering a maximum of seven consecutive days.

Long-Term Studies and Follow-Up

The available evidence is largely derived from research exploring short-term symptom changes, reflecting the use of the product for acute, episodic conditions. Follow-up durations were limited to the time interval needed to monitor cold or allergy symptoms, typically spanning a single dose up to seven days. As follow-up durations were limited, the long-term effects are not fully established. There is limited information for long-term outcomes or the effects of continuous or repeated use over extended periods, as studies generally monitored responses over defined, short time intervals.

Evidence in Special Populations

The combination product was observed in adults and in adolescents aged 12 years and older. For children aged 6 to 11 years, dedicated efficacy trials are generally insufficient. Instead, research in this younger age group includes pharmacokinetic (PK) studies applied in research contexts involving temporary physiological imbalance. These PK studies describe the rate and extent of absorption of the ingredients, but results apply only to the populations studied and cannot guarantee that an individual will respond similarly. Findings describe group patterns, and data for other groups, such as pregnant or older populations, remain insufficient in the context of combination-specific research.

What is Still Uncertain about Gan Ning

Research highlights that follow-up durations were limited, meaning there is limited information for long-term outcomes. Data are still emerging for some subgroups, and the evidence base for younger children is primarily based on extrapolation from adult and PK research. Furthermore, some trials that examined the ingredients for conditions involving heightened symptom activity, such as seasonal allergies, included a third ingredient, meaning the research provides limited insight into the exact symptom patterns for the two-ingredient formulation alone in that context. Comparative evidence against standard treatments remains limited.

Key Studies & References Ibuprofen and Pseudoephedrine Hydrochloride Tablet (FDA DailyMed Label)

Common questions about Gan Ning (FAQ)

Q: Can taking Gan Ning cause extreme tiredness or drowsiness?

A: Regulatory documents state that drowsiness, fatigue, dizziness, and confusion are possible side effects that may occur while taking the medicine. Users should be aware of these potential effects. A health professional can provide individualized guidance regarding any symptoms a user experiences.

Q: Can Gan Ning affect my ability to drive or operate machinery?

A: Official product information indicates that the medicine may affect coordination, reaction time, or judgment due to its components. Official labels include a caution against driving or operating machinery until the user knows how the medicine affects them.

Q: Is the term 'Gan Ning' a brand name or the name of the active ingredient?

A: Gan Ning is a name used to refer to this specific combination product. The medicine contains two distinct active ingredients, Ibuprofen and Pseudoephedrine HCl, which are listed separately on the drug label.

Q: Is Gan Ning known by any other names or generic names?

A: The medicine is a combination of two established generic substances: Ibuprofen and Pseudoephedrine HCl. This combination is marketed globally under various brand names, such as Advil Cold and Sinus, which may differ depending on the manufacturer and country.

Q: Does Gan Ning interact with common painkillers like acetaminophen (Tylenol)?

A: Official information indicates that there are no known serious interactions between the components of this medicine and acetaminophen (Tylenol). However, it is required by regulatory guidelines that daily limits for all medications taken concurrently are observed.

Q: Are there certain supplements or vitamins that should not be taken with Gan Ning?

A: Official information notes that there is limited evidence on safety when combining the components with most herbal remedies. The Ibuprofen component may present an increased risk of bleeding when combined with supplements known to have blood-thinning properties.

Q: How long does it typically take for a person to notice the effects of Gan Ning?

A: The decongestant component, Pseudoephedrine, is generally absorbed rapidly. Studies on the pharmacokinetics (how the body processes the drug) of this component indicate that its onset of action is typically noticed within 15 to 30 minutes after administration.

Q: Is Gan Ning addictive or habit-forming according to regulatory documents?

A: The medicine is not generally classified as addictive or habit-forming on the official label. However, the Pseudoephedrine component is subject to strict governmental regulation regarding its purchase due to its potential misuse in the manufacturing of illegal substances.

Q: What should I do if I suspect a severe or unexpected reaction to Gan Ning?

A: Official labels state that if signs of a severe allergic reaction, vision problems, or symptoms of a heart problem or stroke are experienced, the medicine must be discontinued immediately and emergency medical attention should be sought.

Q: Is Gan Ning available without a prescription in some countries?

A: The medicine is sold as an Over-the-Counter (OTC) product in the United States and several other regions, but its sale is often restricted to behind the pharmacy counter with ID and quantity limits.

Q: Can Gan Ning be taken with antacids or heartburn medication?

A: Official product information documents the need for caution regarding the frequent or high-dose use of antacids, especially those containing aluminum hydroxide. This is because these types of antacids may cause an increase in the concentration of the Pseudoephedrine component in the body.

Q: Are headaches a common concern reported by users of Gan Ning?

A: Headaches are officially listed as a possible side effect of the medicine. The full safety profile, which includes headaches, is detailed in the Adverse Reactions section of the official product information.

Q: Can taking Gan Ning cause a change in blood test results?

A: The medicine may cause changes in certain blood tests. This includes the potential for high blood potassium levels (hyperkalemia) and decreases in red blood cell counts (anemia).

Q: Is Gan Ning a controlled substance?

A: The medicine is not federally classified as a traditional Schedule I-V controlled substance in the U.S. However, its sale is legally restricted by the Combat Methamphetamine Epidemic Act to behind the pharmacy counter with purchase limits due to the Pseudoephedrine component.

Q: Why is eligibility for Gan Ning different in various countries?

A: Eligibility and sales restrictions vary between countries based on local health authority regulations regarding the Pseudoephedrine component. For example, some regions classify it as a Prescription-Only medicine while others allow Over-the-Counter sales with restrictions.

Q: Is Gan Ning known to cause skin rashes or sensitivity to the sun?

A: Regulatory documents state that the medicine is known to cause serious skin reactions, including generalized rash, hives, skin reddening, and blisters. The regulatory warning indicates that the medicine must be stopped and medical help should be sought if these skin reactions occur.

Q: Do official sources provide information on discontinuing Gan Ning?

A: Official warnings describe a requirement for immediate discontinuation if severe symptoms occur, such as signs of a heart problem, stroke, or severe skin reactions. The guidance on administration addresses the duration of treatment.

Q: What does the patient leaflet say about the potential for overdose with Gan Ning?

A: Overdose symptoms may include vomiting, severe drowsiness, agitation, or seizure. In case of a suspected overdose, regulatory information requires that emergency medical attention or a Poison Control Center be contacted immediately.

How to Store and Dispose of Gan Ning?

This medicine, an Ibuprofen and Pseudoephedrine combination, must be stored strictly according to the official regulatory guidelines to maintain its stability and effectiveness.

Official Storage Conditions

The product must be stored at controlled room temperature, typically between 20 C and 25 C. The medication must be kept in its original container and protected from moisture. To prevent compromise of the oral tablet, it is mandated that the medicine must not be frozen and should be kept away from excessive heat.

Child Safety and Disposal

Official labeling requires that Gan Ning be stored safely and out of the sight and reach of children at all times. When the product is expired or unused, it must be disposed of via an authorized community drug take-back program or a local pharmacy collection point. The regulatory instructions prohibit flushing the tablets down the toilet or discarding them in household waste.